$RARE
Ultragenyx Pharmaceutical Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058427 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $127.4M $98.05M
YoY Change 23.27% 8.1%
Cost Of Revenue $12.05M $11.00M
YoY Change 126.57% 27.45%
Gross Profit $115.3M $87.10M
YoY Change 17.66% 6.13%
Gross Profit Margin 90.54% 88.83%
Selling, General & Admin $76.83M $74.92M
YoY Change 5.47% 7.27%
% of Gross Profit 66.61% 86.01%
Research & Development $160.6M $157.2M
YoY Change -6.0% -33.73%
% of Gross Profit 139.2% 180.53%
Depreciation & Amortization $8.216M $7.190M
YoY Change 65.75% 53.17%
% of Gross Profit 7.12% 8.25%
Operating Expenses $237.4M $232.2M
YoY Change -2.57% -24.41%
Operating Profit -$122.0M -$145.1M
YoY Change -16.19% -35.53%
Interest Expense $1.889M $4.500M
YoY Change -76.5% 142.33%
% of Operating Profit
Other Income/Expense, Net -$6.732M -$699.0K
YoY Change -57.1% -36.74%
Pretax Income -$126.9M -$159.0M
YoY Change -17.22% -33.42%
Income Tax -$3.702M $650.0K
% Of Pretax Income
Net Earnings -$123.2M -$159.6M
YoY Change -18.86% -34.87%
Net Earnings / Revenue -96.7% -162.82%
Basic Earnings Per Share -$2.23
Diluted Earnings Per Share -$1.52 -$2.23
COMMON SHARES
Basic Shares Outstanding 82.11M 71.49M
Diluted Shares Outstanding 71.66M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $577.2M $442.1M
YoY Change -22.81% -50.25%
Cash & Equivalents $213.6M $72.58M
Short-Term Investments $363.6M $369.5M
Other Short-Term Assets $47.62M $46.10M
YoY Change -30.92% -35.05%
Inventory $33.97M $31.80M
Prepaid Expenses
Receivables $73.39M $79.26M
Other Receivables $0.00 $0.00
Total Short-Term Assets $732.2M $599.2M
YoY Change -17.16% -40.83%
LONG-TERM ASSETS
Property, Plant & Equipment $290.6M $296.8M
YoY Change 11.87% 26.51%
Goodwill $44.41M $44.41M
YoY Change 0.0% 0.0%
Intangibles $166.3M $157.3M
YoY Change 3.85% -0.69%
Long-Term Investments $199.9M $86.10M
YoY Change 29.38% -29.05%
Other Assets $57.69M $27.90M
YoY Change 242.43% 52.56%
Total Long-Term Assets $758.8M $639.0M
YoY Change 14.71% 5.47%
TOTAL ASSETS
Total Short-Term Assets $732.2M $599.2M
Total Long-Term Assets $758.8M $639.0M
Total Assets $1.491B $1.238B
YoY Change -3.52% -23.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $42.11M $33.36M
YoY Change -2.68% 41.75%
Accrued Expenses $196.5M $178.6M
YoY Change -4.0% -5.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $280.4M $254.0M
YoY Change 7.36% 11.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.21M $10.23M
YoY Change 153.22% 152.59%
Total Long-Term Liabilities $12.21M $10.23M
YoY Change 153.22% 152.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $280.4M $254.0M
Total Long-Term Liabilities $12.21M $10.23M
Total Liabilities $1.216B $1.206B
YoY Change 1.9% 4.94%
SHAREHOLDERS EQUITY
Retained Earnings -$3.388B -$3.264B
YoY Change 21.81% 24.16%
Common Stock $82.00K $72.00K
YoY Change 17.14% 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost) $432.0K $381.0K
YoY Change
Treasury Stock Shares
Shareholders Equity $275.4M $31.71M
YoY Change
Total Liabilities & Shareholders Equity $1.491B $1.238B
YoY Change -3.52% -23.5%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$123.2M -$159.6M
YoY Change -18.86% -34.87%
Depreciation, Depletion And Amortization $8.216M $7.190M
YoY Change 65.75% 53.17%
Cash From Operating Activities -$83.91M -$117.9M
YoY Change -7.12% 23.62%
INVESTING ACTIVITIES
Capital Expenditures $1.597M $3.700M
YoY Change -94.08% -114.21%
Acquisitions
YoY Change
Other Investing Activities -$105.4M $67.99M
YoY Change -27.11% -150.06%
Cash From Investing Activities -$107.0M $64.30M
YoY Change -37.63% -139.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 330.6M 25.23M
YoY Change 17467.06% -94.87%
NET CHANGE
Cash From Operating Activities -83.91M -117.9M
Cash From Investing Activities -107.0M 64.30M
Cash From Financing Activities 330.6M 25.23M
Net Change In Cash 139.7M -28.34M
YoY Change -153.71% -112.08%
FREE CASH FLOW
Cash From Operating Activities -$83.91M -$117.9M
Capital Expenditures $1.597M $3.700M
Free Cash Flow -$85.50M -$121.6M
YoY Change -27.11% 75.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001515673
dei Amendment Flag
AmendmentFlag
false
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2022Q3 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36276
dei Entity Registrant Name
EntityRegistrantName
ULTRAGENYX PHARMACEUTICAL INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2546083
dei Entity Address Address Line1
EntityAddressAddressLine1
60 Leveroni Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Novato
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94949
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
483-8800
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
RARE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82114350
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72575000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
132944000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
369519000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
614818000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
79263000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40445000
CY2023Q3 us-gaap Inventory Net
InventoryNet
31802000
CY2022Q4 us-gaap Inventory Net
InventoryNet
26766000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
46029000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
68926000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
599188000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
883899000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
296811000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
259726000
CY2023Q3 rare Equity Investments Noncurrent
EquityInvestmentsNoncurrent
4039000
CY2022Q4 rare Equity Investments Noncurrent
EquityInvestmentsNoncurrent
5531000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
82071000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
148970000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26427000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25961000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
157302000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160105000
CY2023Q3 us-gaap Goodwill
Goodwill
44406000
CY2022Q4 us-gaap Goodwill
Goodwill
44406000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27896000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16846000
CY2023Q3 us-gaap Assets
Assets
1238140000
CY2022Q4 us-gaap Assets
Assets
1545444000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
33357000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
43274000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
178622000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
204678000
CY2023Q3 rare Contract Liabilities Current
ContractLiabilitiesCurrent
0
CY2022Q4 rare Contract Liabilities Current
ContractLiabilitiesCurrent
1479000
CY2023Q3 rare Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
12067000
CY2022Q4 rare Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
11779000
CY2023Q3 rare Liabilities For Sales Of Future Royalties Current
LiabilitiesForSalesOfFutureRoyaltiesCurrent
29932000
CY2022Q4 rare Liabilities For Sales Of Future Royalties Current
LiabilitiesForSalesOfFutureRoyaltiesCurrent
0
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
253978000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
261210000
CY2023Q3 rare Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
34555000
CY2022Q4 rare Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
19814000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
31667000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
31667000
CY2023Q3 rare Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
875996000
CY2022Q4 rare Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
875439000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10230000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4820000
CY2023Q3 us-gaap Liabilities
Liabilities
1206426000
CY2022Q4 us-gaap Liabilities
Liabilities
1192950000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72174307
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72174307
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70197297
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70197297
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
72000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
70000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
8444
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
381000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2023Q3 us-gaap Treasury Stock Deferred Employee Stock Ownership Plan
TreasuryStockDeferredEmployeeStockOwnershipPlan
381000
CY2022Q4 us-gaap Treasury Stock Deferred Employee Stock Ownership Plan
TreasuryStockDeferredEmployeeStockOwnershipPlan
0
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3298357000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3140019000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2244000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6573000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3264471000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2781022000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
31714000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
352494000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1238140000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1545444000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
98052000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90703000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
306857000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
259981000
CY2023Q3 rare Cost Of Sales
CostOfSales
10987000
CY2022Q3 rare Cost Of Sales
CostOfSales
8631000
rare Cost Of Sales
CostOfSales
33158000
rare Cost Of Sales
CostOfSales
23001000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157245000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
237297000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
487892000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
534981000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
74917000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
69841000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
232966000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
205290000
CY2023Q3 rare Cost Of Sales And Operating Expenses
CostOfSalesAndOperatingExpenses
243149000
CY2022Q3 rare Cost Of Sales And Operating Expenses
CostOfSalesAndOperatingExpenses
315769000
rare Cost Of Sales And Operating Expenses
CostOfSalesAndOperatingExpenses
754016000
rare Cost Of Sales And Operating Expenses
CostOfSalesAndOperatingExpenses
763272000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-145097000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-225066000
us-gaap Operating Income Loss
OperatingIncomeLoss
-447159000
us-gaap Operating Income Loss
OperatingIncomeLoss
-503291000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5881000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3483000
us-gaap Investment Income Interest
InvestmentIncomeInterest
18135000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4876000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1419000
CY2022Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1626000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1492000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-21139000
CY2023Q3 rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
17665000
CY2022Q3 rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
14505000
rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
48676000
rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
27141000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-699000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1105000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2380000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1746000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-158999000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-238819000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-481572000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-548441000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
650000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6287000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1877000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7147000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-159649000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-245106000
us-gaap Net Income Loss
NetIncomeLoss
-483449000
us-gaap Net Income Loss
NetIncomeLoss
-555588000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.23
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.23
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.5
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.96
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71664493
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71664493
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70054173
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70054173
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70987801
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70987801
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69834037
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69834037
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-159649000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-245106000
us-gaap Net Income Loss
NetIncomeLoss
-483449000
us-gaap Net Income Loss
NetIncomeLoss
-555588000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-249000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-420000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
188000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1211000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1103000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-888000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4141000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7607000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
854000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1308000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8818000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4329000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3102000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-564000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
23790000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2973000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4974000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-158795000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-246414000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-479120000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-564406000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
129030000
CY2023Q3 rare Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
24792000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36245000
CY2023Q3 rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
442000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
854000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-159649000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
31714000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
352494000
rare Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
53299000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
100780000
rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
4261000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4329000
us-gaap Net Income Loss
NetIncomeLoss
-483449000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
31714000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
678073000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36096000
CY2022Q3 rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
1074000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1308000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-245106000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
468829000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
922561000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
101862000
rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
8812000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8818000
us-gaap Net Income Loss
NetIncomeLoss
-555588000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
468829000
us-gaap Net Income Loss
NetIncomeLoss
-483449000
us-gaap Net Income Loss
NetIncomeLoss
-555588000
rare Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost
101483000
rare Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost
AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost
101022000
rare Research And Development In Process1
ResearchAndDevelopmentInProcess1
0
rare Research And Development In Process1
ResearchAndDevelopmentInProcess1
75234000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8894000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-4349000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17788000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13263000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1492000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-21139000
rare Non Cash Royalty Revenue
NonCashRoyaltyRevenue
42695000
rare Non Cash Royalty Revenue
NonCashRoyaltyRevenue
15634000
rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
48676000
rare Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
27141000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5496000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16584000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-558000
rare Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities
-14746000
rare Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities
52416000
rare Increase Decrease In Contract Liabilities
IncreaseDecreaseInContractLiabilities
-1479000
rare Increase Decrease In Contract Liabilities
IncreaseDecreaseInContractLiabilities
-6118000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-390902000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-290123000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42667000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89153000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
75391000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
304789000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
416161000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
47520000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
82966000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
582230000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
407926000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2500000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
30000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
4777000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
240000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
275017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-120053000
rare Proceeds From Royalties Received Financing Activities
ProceedsFromRoyaltiesReceivedFinancingActivities
0
rare Proceeds From Royalties Received Financing Activities
ProceedsFromRoyaltiesReceivedFinancingActivities
490950000
rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
53299000
rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
0
rare Payments For Proceeds From Issuance Of Common Stock Under Equity Plan
PaymentsForProceedsFromIssuanceOfCommonStockUnderEquityPlan
-4261000
rare Payments For Proceeds From Issuance Of Common Stock Under Equity Plan
PaymentsForProceedsFromIssuanceOfCommonStockUnderEquityPlan
-8812000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-28000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-436000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57532000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
499326000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-641000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2427000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58994000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
86723000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
137601000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
309585000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78607000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
396308000
rare Operating And Finance Lease Liability From Obtaining Right Of Use Assets
OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets
23360000
rare Operating And Finance Lease Liability From Obtaining Right Of Use Assets
OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets
1168000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
2562000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
619000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1427000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20435000
rare Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment
NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment
9430000
rare Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment
NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment
7820000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">1. Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Ultragenyx Pharmaceutical Inc., or the Company, is a biopharmaceutical company incorporated in Delaware.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. The Company operates as </span><span style="font-size:10pt;font-family:'Calibri',sans-serif;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> reportable segment and has four commercially approved products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Crysvita® (burosumab) is approved in the United States, or U.S., the European Union, or EU, and certain other regions for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Crysvita is also approved in the U.S. and certain other regions for the treatment of fibroblast growth factor 23, or FGF23,-related hypophosphatemia in tumor-induced osteomalacia, or TIO, associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Mepsevii® (vestronidase alfa) is approved in the U.S., the EU and certain other regions, as the first medicine for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Dojolvi® (triheptanoin) is approved in the U.S. and certain other regions for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Evkeeza® (evinacumab) is approved in the U.S. and the European Economic Area, or EEA, for the treatment of homozygous familial hypercholesterolemia, or HoFH. The Company has exclusive rights to commercialize Evkeeza® (evinacumab) outside of the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In addition to the approved products, the Company has the following ongoing clinical development programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">UX111 (formerly ABO-102) is an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease;</span></div></div><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">DTX401 is an adeno-associated virus 8, or AAV8, gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia, or GSDIa;</span></div></div><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">DTX301 is an AAV8 gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase, or OTC deficiency, the most common urea cycle disorder;</span></div></div><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">UX143 (setrusumab), which is subject to the Company’s collaboration agreement with Mereo BioPharma 3, or Mereo, is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells for the treatment of patients with osteogenesis imperfect, or OI; </span></div></div><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">GTX-102 is an antisense oligonucleotide, or ASO, for the treatment of Angelman syndrome, a debilitating and rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene;</span></div></div><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">UX701 is an adeno-associated virus 9, or AAV9, gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease; and</span></div></div><div style="margin-left:3.333%;text-indent:0;display:flex;margin-top:4.5pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">UX053 is a messenger RNA, or mRNA, product candidate designed for the treatment of patients with Glycogen Storage Disease Type III, or GSDIII, a disease caused by a glycogen debranching enzyme, or AGL, deficiency that results in glycogen accumulation in the liver and muscle.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">’</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">s ultimate success depends on the outcome of its research and development and commercialization activities. Through September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, the Company has relied primarily on its sale of equity securities, its revenues from commercial products, its sale of future royalties, and strategic collaboration arrangements to finance its operations. The Company expects it will need to raise additional capital to fully implement its business plans through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP. The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, revenue recognition, and the liabilities for sales of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72575000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391651000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1976000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
517000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4056000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4140000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78607000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
396308000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
19173000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
17486000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
507017000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
884017000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
497399000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1627000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
495812000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
882363000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
407000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6135000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
876635000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12629000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9280000
CY2023Q3 us-gaap Inventory Net
InventoryNet
31802000
CY2022Q4 us-gaap Inventory Net
InventoryNet
26766000
CY2023Q3 rare Research Clinical Study And Manufacturing Expenses
ResearchClinicalStudyAndManufacturingExpenses
51520000
CY2022Q4 rare Research Clinical Study And Manufacturing Expenses
ResearchClinicalStudyAndManufacturingExpenses
73558000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
76300000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
78938000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50802000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52182000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
178622000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
204678000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
98052000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90703000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
306857000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
259981000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
98052000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90703000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
306857000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
259981000
CY2022Q4 rare Contract With Customer Assets Liability Current
ContractWithCustomerAssetsLiabilityCurrent
1479000
CY2021Q4 rare Contract With Customer Assets Liability Current
ContractWithCustomerAssetsLiabilityCurrent
9076000
rare Contract With Customer Liability Additions During Period
ContractWithCustomerLiabilityAdditionsDuringPeriod
0
rare Contract With Customer Liability Additions During Period
ContractWithCustomerLiabilityAdditionsDuringPeriod
89000
rare Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
1479000
rare Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
6207000
CY2023Q3 rare Contract With Customer Assets Liability Current
ContractWithCustomerAssetsLiabilityCurrent
0
CY2022Q3 rare Contract With Customer Assets Liability Current
ContractWithCustomerAssetsLiabilityCurrent
2958000
CY2021Q4 rare Liability For Sale Of Future Royalties
LiabilityForSaleOfFutureRoyalties
351786000
CY2022 rare Proceeds From Royalties Received Financing Activities
ProceedsFromRoyaltiesReceivedFinancingActivities
490950000
CY2022 rare Royalty Revenue
RoyaltyRevenue
21692000
CY2022 rare Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment
NonCashInterestExpenseOnLiabilityForSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment
54395000
CY2022Q4 rare Liability For Sale Of Future Royalties
LiabilityForSaleOfFutureRoyalties
875439000
rare Royalty Revenue
RoyaltyRevenue
27617000
rare Non Cash Interest Expense On Liability For Sale Of Future Royalties And Capitalized To Property Plant And Equipment
NonCashInterestExpenseOnLiabilityForSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment
58106000
CY2023Q3 rare Liability For Sale Of Future Royalties
LiabilityForSaleOfFutureRoyalties
905928000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34877000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35761000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
101469000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
101013000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14651749
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12014181
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14154897
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11129869
CY2023Q3 rare Stock Issued During Period Shares At Market Offering
StockIssuedDuringPeriodSharesAtMarketOffering
611282
rare Stock Issued During Period Shares At Market Offering
StockIssuedDuringPeriodSharesAtMarketOffering
1175584
CY2023Q3 rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
24800000
rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
53300000
rare Related Party Payment Of Contribution
RelatedPartyPaymentOfContribution
1000000
CY2022Q3 rare Related Party Transaction Contribution Period
RelatedPartyTransactionContributionPeriod
P4Y
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-657000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-845000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1587000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5728000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2244000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6573000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
rare-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-058427-index-headers.html Edgar Link pending
0000950170-23-058427-index.html Edgar Link pending
0000950170-23-058427.txt Edgar Link pending
0000950170-23-058427-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img215930992_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rare-20230930.htm Edgar Link pending
rare-20230930.xsd Edgar Link pending
rare-ex31_1.htm Edgar Link pending
rare-ex31_2.htm Edgar Link pending
rare-ex32_1.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rare-20230930_def.xml Edgar Link unprocessable
rare-20230930_lab.xml Edgar Link unprocessable
rare-20230930_pre.xml Edgar Link unprocessable
rare-20230930_htm.xml Edgar Link completed